Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

ALP70-50UG Apolipoprotein E, human

Apolipoprotein E, human MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Key Applications: Positive Control UniProt Number: P02649 Entrez Gene Number: NM_000041.2
ALP70-50UG
50 µg  
Purchase on Sigma-Aldrich

Przegląd

Replacement Information
Description
Catalogue NumberALP70-50UG
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionApolipoprotein E, human
OverviewMOLECULAR WEIGHT:

34,200
Alternate Names
  • ApoE
Background InformationApolipoprotein E serves as a ligand for low density receptors and participates in the transport and redistribution of cholesterol and other lipids. Other functions include immunoregulation and cell growth modulation and differentiation. Apo E is thought to be involved in tissue repair as increase amounts of the protein are found at sites or peripheral nerve injury and regeneration. A mutant form is associated with familial type hyperlipoproteinemia.
References
Product Information
PresentationLiquid in 10 mM NH4HCO3, pH 8.0.
Quality LevelMQ100
Applications
Key Applications
  • Positive Control
Biological Information
Concentration0.276 mg/mL
Purity≤95% by SDS-PAGE
SourceHuman plasma tested negative for HBsAg and HIV-I, HIV-II, HBc and Hepatitis C antibodies. All blood products should be treated as potentially infectious.
Entrez Gene Number
Entrez Gene SummaryChylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.
Gene Symbol
  • APOE
  • Apo-E
  • apoprotein
  • MGC1571
  • AD2
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P02649 # Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.
SIZE: 317 amino acids; 36154 Da
SUBCELLULAR LOCATION: Secreted.
TISSUE SPECIFICITY: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
PTM: Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. & Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).
DISEASE: SwissProt: P02649 # Defects in APOE are a cause of hyperlipoproteinemia type III [MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with hyperlipoproteinemia type III, are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of hyperlipoproteinemia type III have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD. & The APOE*4 allele is associated with late onset Alzheimer disease 2 (AD2) [MIM:104310]. The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known. & Defects in APOE are a cause of sea-blue histiocyte disease [MIM:269600]; also called sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.
SIMILARITY: SwissProt: P02649 ## Belongs to the apolipoprotein A1/A4/E family.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsMaintain at -20ºC or below in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles. All blood products should be treated as potentially infectious.
Packaging Information
Material Size50 µg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numer katalogowy GTIN
ALP70-50UG 04053252273414

Documentation

Apolipoprotein E, human MSDS

Title

Safety Data Sheet (SDS) 

Apolipoprotein E, human Certificates of Analysis

TitleLot Number
HUMAN APOLIPOPROTEIN E PURIFIED - 2139987 2139987
HUMAN APOLIPOPROTEIN E - 2528757 2528757
HUMAN APOLIPOPROTEIN E - 3236395 3236395
HUMAN APOLIPOPROTEIN E - 3254592 3254592
HUMAN APOLIPOPROTEIN E - 3420933 3420933
HUMAN APOLIPOPROTEIN E - 3543939 3543939
HUMAN APOLIPOPROTEIN E - 3583916 3583916
HUMAN APOLIPOPROTEIN E - 3695877 3695877
HUMAN APOLIPOPROTEIN E - 3745907 3745907
HUMAN APOLIPOPROTEIN E - 3777291 3777291
Show more